Pathogenic gain-of-function mutations in the gene encoding phosphoinositide 3-kinase delta (PI3Kδ) cause activated PI3Kδ syndrome (APDS), a disease characterized by humoral immunodeficiency, lymphadenopathy, and an inability to control persistent viral infections including Epstein-Barr virus (EBV) and cytomegalovirus (CMV) infections. Understanding the mechanisms leading to impaired immune response is important to optimally treat APDS patients. Immunosenescence of CD8 T cells was suggested to contribute to APDS pathogenesis. However, the constitutive activation of T cells in APDS may also result in T cell exhaustion. Therefore, we studied exhaustion of the CD8 T cell compartment in APDS patients and compared them with healthy controls and HIV patients, as a control for exhaustion. The subset distribution of the T cell compartment of APDS patients was comparable with HIV patients with decreased naive CD4 and CD8 T cells and increased effector CD8 T cells. Like in HIV patients, expression of activation markers and inhibitory receptors CD160, CD244, and programmed death receptor (PD)-1 on CD8 T cells was increased in APDS patients, indicating exhaustion. EBV-specific CD8 T cells from APDS patients exhibited an exhausted phenotype that resembled HIV-specific CD8 T cells in terms of inhibitory receptor expression. Inhibition of PD-1 on EBV-specific CD8 T cells from APDS patients enhanced proliferation and effector cytokine production. Based on these results, we conclude that total and EBV-specific CD8 T cells from APDS patients are characterized by T cell exhaustion. Furthermore, PD-1 checkpoint inhibition may provide a possible therapeutic approach to support the immune system of APDS patients to control EBV and CMV.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5845988PMC
http://dx.doi.org/10.3389/fimmu.2018.00446DOI Listing

Publication Analysis

Top Keywords

apds patients
32
cd8 cells
32
cells apds
16
cell compartment
12
patients
12
hiv patients
12
ebv-specific cd8
12
apds
11
cd8
9
cells
9

Similar Publications

Context: Osteonecrosis (ON) is bone death caused by inadequate blood supply and its optimal management remains uncertain.

Objective: We describe the outcomes of BP (pamidronate) treatment in our patients.

Design: Data regarding clinical, laboratory, magnetic resonance imaging (MRI) studies, and bone mineral density measurements (BMD) were recorded before and one year after treatment (reevaluation).

View Article and Find Full Text PDF

Introduction: Osteogenesis imperfecta is a rare inherited connective tissue disorder that results in excessive bone fragility due to defects in collagen production. The majority of osteogenesis imperfecta cases are inherited in an autosomal dominant pattern, and 17 genetic causes have been identified. Diagnosis is usually based on clinical presentation and low bone mineral density scores, while treatment involves a multidisciplinary approach using medical therapies such as bisphosphonates, vitamin C, and pamidronate.

View Article and Find Full Text PDF

Schizophrenia is a chronic and severe mental disorder. It is currently treated with antipsychotic drugs (APD). However, APD's work only in a limited number of patients and may have cognition impairing side effects.

View Article and Find Full Text PDF

OI, or bone brittle disease, is characterized by increased mineralization of bone matrix independently of clinical severity. So, a beneficial effect of antiresorptive treatments such as bisphosphonates (BP) is questionable. We aim to compare the bone matrix characteristics before and after BP pamidronate (PAM).

View Article and Find Full Text PDF

Chapter 12: PREPARATION FOR PARATHYROID SURGERY.

Ann Endocrinol (Paris)

January 2025

Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, AP-HP, Hôpital Bicêtre, Service d'Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares du Métabolisme du Calcium et du Phosphate, 94 275 Le Kremlin Bicêtre, France. Electronic address:

Preoperative treatment of PHPT aims to 1) manage severe and/or symptomatic hypercalcemia and 2) prevent postoperative hypocalcemia. Severe hypercalcemia, defined as a blood calcium level ≥ 3.5 mmol/L, requires admission to hospital in a conventional or critical care unit, depending on clinical symptoms and comorbidities.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!